糖皮质激素。

Glucocorticoids.

机构信息

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany.

出版信息

Best Pract Res Clin Rheumatol. 2011 Dec;25(6):891-900. doi: 10.1016/j.berh.2011.11.002.

DOI:10.1016/j.berh.2011.11.002

PMID:22265268

Abstract

Glucocorticoids remain part of the treatment strategy in many rheumatic diseases, because of their anti-inflammatory and immunosuppressive actions. Unfortunately, their clinically desired effects are linked to adverse effects, especially at higher dosages and longer duration of treatment. In this review, we describe new insights into the mechanisms of anti-inflammatory glucocorticoid actions and provide an update on recent approaches to improve the risk/benefit ratio of glucocorticoid therapy. Improved knowledge of the immunomodulatory role of endogenous glucocorticoids has evolved, and we report on the therapeutic potential of targeting glucocorticoid pre-receptor metabolism for metabolic and inflammatory diseases.

摘要

糖皮质激素因其抗炎和免疫抑制作用，仍然是许多风湿性疾病治疗策略的一部分。不幸的是，它们的临床预期效果与不良反应相关，尤其是在更高剂量和更长的治疗时间下。在这篇综述中，我们描述了抗炎糖皮质激素作用机制的新见解，并提供了关于改善糖皮质激素治疗风险/效益比的最新方法的更新。对内源性糖皮质激素的免疫调节作用的认识不断发展，我们报告了针对糖皮质激素前体代谢的治疗潜力，用于代谢和炎症性疾病。